BIOCONstockBiocon Ltd
₹411.5
▼-1.15%
Open
₹421.35
High
₹421.35
Low
₹406.5
Volume
1.69M
Price chart
Daily close · downsampled 5-year history
2021-06-21 · ₹405.552026-06-18 · ₹414.05
Instrument details
- MB Code
- MBEQU2741
- Type
- stock
- ISIN
- INE376G01013
- BSE
- 532523
- Industry
- Pharmaceuticals & Biotechnology
Latest earnings
Q4FY26 declared
- Quarter
- Mar 2026
- Revenue
- 4516.6 Cr
- Net profit
- 198.6 Cr
- EPS
- 0.79
- YoY revenue
- +2.25%
Price returns
Historical performance
- 1 day
- +0.57%
- 1 month
- -3.25%
- 3 months
- +8.70%
- 1 year
- +21.01%
- 3 years
- +69.14%
- 5 years
- +3.73%
Technicals
Indicator consensus
Bullish
22
Neutral
7
Bearish
17
RSI 44.66(Neutral)
Company documents
Annual reports, concalls, presentations
Concall transcripts
90Investor presentations
98Corporate announcements
548Corporate timeline
Price chart events · 1 year
Dividend
2025-07-04
{"amount":0.5}
Dividend
2026-07-03
{"amount":0.5}
Earnings
2025-08-07
{"actualRevenue":39419000000,"estimateRevenue":40010000000,"revenueSurprise":-591000000,"revenueSurprisePercent":-1.47713071732067,"actualEPS":0.26,"estimateEPS":0.7608633,"surprise":-0.5008633,"surprisePercent":-65.82829004894835}
Earnings
2026-02-12
{"actualRevenue":41730000000,"estimateRevenue":45429000000,"revenueSurprise":-3699000000,"revenueSurprisePercent":-8.14237601532061,"actualEPS":2.75,"estimateEPS":1.2221,"surprise":1.5279,"surprisePercent":125.022502250225}
Earnings
2025-11-11
{"actualRevenue":42955000000,"estimateRevenue":42158000000,"revenueSurprise":797000000,"revenueSurprisePercent":1.890507139807391,"actualEPS":0.74,"estimateEPS":0.55045,"surprise":0.18955,"surprisePercent":34.43546189481334}
Earnings
2026-05-07
{"actualRevenue":45166000000,"estimateRevenue":45693000000,"revenueSurprise":-527000000,"revenueSurprisePercent":-1.153349528374149,"actualEPS":1.29,"estimateEPS":1.2019,"surprise":0.08810000000000007,"surprisePercent":7.33006073716616}
News
2026-05-08
{"description":"Biocon says biosimilars traction in the US and merger-led synergies should aid margins through FY27, with nearly ₹300 crore interest-cost savings and broader GLP-1/insulin filings planned.","url":"https://www.cnbctv18.com/market/earnings/biocon-biosimilars-growth-merger-synergies-oncology-insulin-19901962.htm","sentiment":"Positive","domain":"CNBCTV18"}
News
2026-03-27
{"description":"Biocon shares fell over 3% on Friday, March 27 after CEO & MD Siddharth Mittal resigned; company said he will transition to a new role, prompting market reaction.","url":"https://www.ndtvprofit.com/markets/biocon-shares-fall-over-3-after-ceo-md-siddharth-mittal-resigns-11273157","sentiment":"Negative","domain":"NDTV Profit"}
News
2026-02-25
{"description":"Biocon said it received US FDA approval for its Liraglutide Injection, a complex formulation for chronic weight management, enabling the company to market the drug in the United States.","url":"https://www.business-standard.com/markets/capital-market-news/biocon-gets-us-fda-nod-for-chronic-weight-management-drug-liraglutide-126022500236_1.html","sentiment":"Positive","domain":"Business Standard"}
News
2026-02-12
{"description":"Biocon reported consolidated Q3 (ended Dec 2025) net profit of Rs 144 crore vs Rs 25 crore year‑ago; revenue Rs 4,173 crore. Board approved buying remaining 2% of Biocon Biologics; debt cuts to save ~Rs 300 cr/yr from FY27.","url":"https://money.rediff.com/news/market/biocon-q3-profit-surges-to-rs-144-cr/41923020260212","sentiment":"Positive","domain":"Rediff Money"}